Wall Street analysts predict that Heska Corp (NASDAQ:HSKA) will post earnings per share of $0.03 for the current quarter, Zacks reports. Two analysts have made estimates for Heska’s earnings. The highest EPS estimate is $0.10 and the lowest is ($0.05). Heska reported earnings per share of $0.46 in the same quarter last year, which indicates a negative year-over-year growth rate of 93.5%. The company is expected to issue its next earnings report on Tuesday, February 25th.
According to Zacks, analysts expect that Heska will report full year earnings of $0.05 per share for the current financial year, with EPS estimates ranging from ($0.02) to $0.12. For the next financial year, analysts forecast that the firm will post earnings of $0.19 per share, with EPS estimates ranging from $0.03 to $0.34. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Heska.
Heska (NASDAQ:HSKA) last issued its earnings results on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). Heska had a return on equity of 3.17% and a net margin of 3.15%. The company had revenue of $31.24 million for the quarter, compared to analyst estimates of $30.44 million.
HSKA has been the topic of a number of research reports. Raymond James lowered Heska from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. They noted that the move was a valuation call. ValuEngine raised Heska from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. BidaskClub raised Heska from a “hold” rating to a “buy” rating in a research report on Thursday, October 31st. Piper Jaffray Companies initiated coverage on Heska in a research report on Wednesday, September 18th. They set a “neutral” rating and a $68.00 target price on the stock. Finally, Canaccord Genuity reissued a “buy” rating and issued a $105.00 price target (up from $75.00) on shares of Heska in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $85.75.
Shares of NASDAQ:HSKA traded up $2.27 during trading on Monday, reaching $94.69. 1,120 shares of the stock were exchanged, compared to its average volume of 103,102. The company has a debt-to-equity ratio of 0.31, a current ratio of 8.52 and a quick ratio of 6.80. Heska has a 1-year low of $62.47 and a 1-year high of $105.00. The stock has a fifty day moving average of $81.17 and a two-hundred day moving average of $77.32. The firm has a market cap of $721.62 million, a price-to-earnings ratio of 66.68 and a beta of 1.06.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. purchased a new stake in Heska in the 2nd quarter valued at $29,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Heska by 175.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 670 shares of the medical research company’s stock valued at $47,000 after buying an additional 427 shares during the last quarter. Aperio Group LLC purchased a new stake in Heska in the 2nd quarter valued at $79,000. Quantamental Technologies LLC purchased a new stake in Heska in the 2nd quarter valued at $120,000. Finally, Bank of Montreal Can raised its position in Heska by 30.3% in the 2nd quarter. Bank of Montreal Can now owns 2,162 shares of the medical research company’s stock valued at $183,000 after buying an additional 503 shares during the last quarter. 92.98% of the stock is owned by institutional investors and hedge funds.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
For more information about research offerings from Zacks Investment Research, visit Zacks.com